EA201201177A1 - Димерные ингибиторы iap - Google Patents

Димерные ингибиторы iap

Info

Publication number
EA201201177A1
EA201201177A1 EA201201177A EA201201177A EA201201177A1 EA 201201177 A1 EA201201177 A1 EA 201201177A1 EA 201201177 A EA201201177 A EA 201201177A EA 201201177 A EA201201177 A EA 201201177A EA 201201177 A1 EA201201177 A1 EA 201201177A1
Authority
EA
Eurasian Patent Office
Prior art keywords
iap
dimeric inhibitors
dimeric
formula
inhibitors
Prior art date
Application number
EA201201177A
Other languages
English (en)
Russian (ru)
Inventor
Кристофер Шон Страуб
Чжуолян Чэнь
Марк Г. Палермо
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of EA201201177A1 publication Critical patent/EA201201177A1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
EA201201177A 2010-02-25 2011-02-23 Димерные ингибиторы iap EA201201177A1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US30811410P 2010-02-25 2010-02-25
US33392710P 2010-05-12 2010-05-12
US38841010P 2010-09-30 2010-09-30
PCT/EP2011/052662 WO2011104266A1 (en) 2010-02-25 2011-02-23 Dimeric iap inhibitors

Publications (1)

Publication Number Publication Date
EA201201177A1 true EA201201177A1 (ru) 2013-04-30

Family

ID=44476672

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201201177A EA201201177A1 (ru) 2010-02-25 2011-02-23 Димерные ингибиторы iap

Country Status (13)

Country Link
US (1) US8445440B2 (https=)
EP (1) EP2539333A1 (https=)
JP (1) JP2013520466A (https=)
KR (1) KR20130010894A (https=)
CN (1) CN102834389A (https=)
AR (1) AR080253A1 (https=)
BR (1) BR112012021291A2 (https=)
CA (1) CA2790302A1 (https=)
EA (1) EA201201177A1 (https=)
MX (1) MX2012009894A (https=)
TW (1) TW201141846A (https=)
UY (1) UY33236A (https=)
WO (1) WO2011104266A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100317593A1 (en) * 2009-06-12 2010-12-16 Astrazeneca Ab 2,3-dihydro-1h-indene compounds
UY33794A (es) * 2010-12-13 2012-07-31 Novartis Ag Inhibidores diméricos de las iap
CA2850330A1 (en) 2011-09-30 2013-04-04 Tetralogic Pharmaceuticals Corporation Smac mimetic (birinapant) for use in the treatment of proliferative diseases (cancer)
WO2014025759A1 (en) * 2012-08-09 2014-02-13 Bristol-Myers Squibb Company Iap antagonists
TW201428002A (zh) * 2012-11-09 2014-07-16 必治妥美雅史谷比公司 用於抑制細胞凋亡抑制劑之巨環化合物
CN105451726B (zh) 2013-06-25 2021-03-16 沃尔特和伊利莎豪医学研究所 治疗细胞内感染的方法
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
CN109705191B (zh) * 2017-10-25 2022-04-29 广东东阳光药业有限公司 Iap抑制剂及其在药物中的应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6041077B2 (ja) 1976-09-06 1985-09-13 喜徳 喜谷 1,2‐ジアミノシクロヘキサン異性体のシス白金(2)錯体
US5281620A (en) 1986-12-23 1994-01-25 Cancer Research Campaign Technology Limited Compounds having antitumor and antibacterial properties
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
GB0018891D0 (en) 2000-08-01 2000-09-20 Novartis Ag Organic compounds
JP2002037626A (ja) 2000-07-27 2002-02-06 Internatl Superconductivity Technology Center ビスマス系高温超電導体の製造方法。
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
US7229617B2 (en) 2002-11-27 2007-06-12 Irm Llc Methods and compositions for inducing apoptosis in cancer cells
KR20060126548A (ko) 2004-02-05 2006-12-07 노파르티스 아게 (a) DNA 토포이소머라제 억제제 및 (b) IAP 억제제조합물
CN1926118A (zh) 2004-03-01 2007-03-07 德克萨斯大学董事会 二聚的小分子细胞凋亡增强剂
AU2005274937B2 (en) 2004-07-15 2011-08-18 Medivir Ab IAP binding compounds
ES2456671T3 (es) 2005-02-25 2014-04-23 Tetralogic Pharmaceuticals Corporation Inhibidores diméricos de IAP
US7772177B2 (en) 2005-05-18 2010-08-10 Aegera Therapeutics, Inc. BIR domain binding compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
WO2007021825A2 (en) 2005-08-09 2007-02-22 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
WO2007048224A1 (en) 2005-10-25 2007-05-03 Aegera Therapeutics Inc. Iap bir domain binding compounds
WO2007075525A2 (en) 2005-12-20 2007-07-05 Novartis Ag Combination of an iap-inhibitor and a taxane7
TWI504597B (zh) 2006-03-16 2015-10-21 Pharmascience Inc 結合於細胞凋亡抑制蛋白(iap)之桿狀病毒iap重複序列(bir)區域之化合物
BRPI0708942A2 (pt) 2006-03-21 2011-06-14 Joyant Pharmaceuticals Inc composto promotor de apoptose, uso e mÉtodo de produÇço do mesmo e composiÇço farmacÊutica
US8202902B2 (en) 2006-05-05 2012-06-19 The Regents Of The University Of Michigan Bivalent SMAC mimetics and the uses thereof
AU2007250443B2 (en) 2006-05-16 2013-06-13 Pharmascience Inc. IAP BIR domain binding compounds
KR20090041391A (ko) 2006-07-24 2009-04-28 테트랄로직 파마슈티칼스 이량체성 iap 길항제
CL2007002166A1 (es) 2006-07-24 2008-01-25 Tetralogic Pharm Corp Compuestos derivados de heterociclos de nitrogeno, antagonistas de los inhibidores de las proteinas de la apoptosis; sus composiciones farmaceuticas; y uso de dichos compuestos para el tratamiento del cancer.
WO2008014240A2 (en) 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
US20100056495A1 (en) 2006-07-24 2010-03-04 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
WO2008014229A2 (en) 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
WO2008014238A2 (en) 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
PE20110220A1 (es) 2006-08-02 2011-04-11 Novartis Ag DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
KR20090082221A (ko) 2006-10-19 2009-07-29 노파르티스 아게 유기 화합물
CN101541325A (zh) * 2006-11-28 2009-09-23 诺瓦提斯公司 Iap抑制剂用于治疗急性髓性白血病的用途
WO2008066854A2 (en) 2006-11-28 2008-06-05 Novartis Ag Methods and compositions for inducing apoptosis in cancer cells
KR101149449B1 (ko) 2007-03-20 2012-05-25 삼성전자주식회사 오디오 신호의 인코딩 방법 및 장치, 그리고 오디오 신호의디코딩 방법 및 장치
JP5454943B2 (ja) 2007-04-12 2014-03-26 ジョイアント ファーマスーティカルズ、インク. 抗癌剤として有用なsmac模倣二量体及び三量体
PE20130150A1 (es) 2007-04-30 2013-02-27 Genentech Inc Inhibidores de las iap
JP2010528587A (ja) 2007-05-07 2010-08-26 テトラロジック ファーマシューティカルズ コーポレーション アポトーシス阻害タンパク質のアンタゴニストに対する感受性のバイオマーカーとしてTNFα遺伝子の発現を用いる方法
AU2008298948B2 (en) 2007-09-12 2014-09-04 F. Hoffmann-La Roche Ag Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
US8354528B2 (en) 2007-10-25 2013-01-15 Genentech, Inc. Process for making thienopyrimidine compounds
EP2058312A1 (en) 2007-11-09 2009-05-13 Universita' degli Studi di Milano SMAC mimetic compounds as apoptosis inducers
ES2398791T3 (es) 2008-01-11 2013-03-21 Genentech, Inc. Inhibidores de IAP
EP2242362A4 (en) 2008-01-24 2012-04-11 Tetralogic Pharm Corp IAP INHIBITORS
WO2009136290A1 (en) 2008-05-05 2009-11-12 Aegera Therapeutics, Inc. Functionalized pyrrolidines and use thereof as iap inhibitors
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
WO2009155709A1 (en) 2008-06-27 2009-12-30 Aegera Therapeutics Inc. Bridged secondary amines and use thereof as iap bir domain binding compounds
CN102171209A (zh) 2008-08-02 2011-08-31 健泰科生物技术公司 Iap抑制剂
WO2010015090A1 (en) 2008-08-07 2010-02-11 Aegera Therapeutics Inc. Functionalized pyrrolidines and use thereof as iap inhibitors
AU2009293403A1 (en) 2008-09-17 2010-03-25 Tetralogic Pharmaceuticals Corp. IAP inhibitors
EP2350641B1 (en) 2008-09-22 2014-09-24 Amgen Inc. A combination of a tnf alpha inhibitor, an iap inhibitor and a trail receptor agonist for use in treating cancer
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic

Also Published As

Publication number Publication date
US8445440B2 (en) 2013-05-21
US20110206690A1 (en) 2011-08-25
AR080253A1 (es) 2012-03-21
TW201141846A (en) 2011-12-01
UY33236A (es) 2011-09-30
CA2790302A1 (en) 2011-09-01
EP2539333A1 (en) 2013-01-02
MX2012009894A (es) 2012-09-12
WO2011104266A1 (en) 2011-09-01
CN102834389A (zh) 2012-12-19
KR20130010894A (ko) 2013-01-29
AU2011219862A1 (en) 2012-09-06
JP2013520466A (ja) 2013-06-06
BR112012021291A2 (pt) 2016-10-25

Similar Documents

Publication Publication Date Title
EA201201177A1 (ru) Димерные ингибиторы iap
JOP20180104A1 (ar) مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
JOP20180103A1 (ar) مركب صيدلاني
EA201491412A1 (ru) Соединения для лечения спинальной мышечной атрофии
UA110354C2 (uk) Противірусні сполуки
EA201491766A1 (ru) Соединения для лечения спинальной мышечной атрофии
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
EA201491786A1 (ru) ТРИАЗОЛОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ mPGES-1
JO3131B1 (ar) مركبات كيميائية
EA201590005A1 (ru) Замещенные трициклические соединения как ингибиторы fgfr
EA201692166A1 (ru) Гетероциклические ингибиторы глютаминазы
UA115231C2 (uk) Сполуки імідазопіролідинонів
EA201200323A1 (ru) Соединения и композиции, как ингибиторы протеинкиназы
TR201816379T4 (tr) DNA-PK inhibitörleri.
EA201691354A1 (ru) Терапевтические ингибирующие соединения
EA201400412A1 (ru) ЗАМЕЩЕННЫЕ БЕНЗИЛИНДАЗОЛЫ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Bub1 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ
EA201390609A1 (ru) ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ
JO3515B1 (ar) مثبطات fgfr4 بيريميدين
EA201492002A1 (ru) Противовирусные соединения
EA201491151A1 (ru) Соединения, ингибирующие металлоферменты
EA201391390A1 (ru) Циклопропиламины в качестве ингибиторов lsd
EA201291357A1 (ru) Способы лечения с применением ингибиторов tlr7 и/или tlr9
EA201490423A1 (ru) СПОСОБЫ И КОМПОЗИЦИИ, ОТНОСЯЩИЕСЯ К p62, ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ РАКА
EA201691574A1 (ru) Конденсированное бициклическое 2,4-диаминопиримидиновое производное в качестве двойного alk и fak ингибитора
EA201201661A1 (ru) Новые аминопиразолохиназолины